DEF 14A: Alector, Inc. Announces Details for 2024 Annual Stockholders Meeting
Proxy Statement
Alector, Inc. has scheduled its 2024 annual meeting of stockholders for June 12, 2024, to address director elections, auditor ratification, executive compensation, and other business matters.
Summary
- Alector, Inc. will hold its 2024 annual meeting of stockholders virtually on June 12, 2024, at 8:00 a.m. Pacific Time.
- Stockholders of record as of April 16, 2024, are eligible to vote.
- The meeting will address the election of three Class III directors, ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
- The Board of Directors recommends voting for the election of Louis J. Lavigne, Jr., Richard H. Scheller, Ph.D., and Mark Altmeyer as Class III directors.
- The Board also recommends voting for the ratification of Ernst & Young LLP and the approval of executive compensation.
- The Notice of Internet Availability of Proxy Materials was first mailed on or about April 25, 2024.
- Stockholders can vote online, by telephone, or by mail.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspects include the recommendation to vote for all proposals and the high approval rate of the say-on-pay vote in 2023. The negative aspects are limited to the inherent risks associated with corporate governance structures.
Positives
- The Board of Directors recommends voting 'FOR' all proposals.
- In 2023, our stockholders approved the say-on-pay vote with 94% of the votes cast (excluding broker non-votes and abstentions) in support of the compensation of our named executive officers as disclosed in our 2023 proxy statement.
Risks
- The classification of the Board of Directors may have the effect of delaying or preventing a change-in-control of Alector.
Future Outlook
Alector intends to submit the executive compensation of its named executive officers to an advisory vote at its annual meeting of stockholders each year until the say-when-on-pay proposal is brought before stockholders again.
Industry Context
This announcement is typical for publicly traded companies as they prepare for their annual meetings, ensuring compliance with SEC regulations and corporate governance best practices. The focus on executive compensation, board composition, and auditor selection are standard agenda items.
Comparison to Industry Standards
- The peer group selection criteria, including industry sector, stage of development, market capitalization, and employee headcount, are consistent with industry practices for benchmarking executive compensation.
- The use of independent compensation consultants like Pearl Meyer is a common practice among publicly traded companies to ensure objectivity in executive pay decisions.
- The mix of cash and equity compensation, with a higher emphasis on long-term equity incentives, aligns with industry trends to incentivize executives to drive long-term shareholder value.
- The adoption of a clawback policy and anti-hedging/anti-pledging policies reflects a commitment to strong corporate governance, similar to practices at companies like Amgen, Biogen, and Gilead Sciences.
Related Party Transactions
- Alector has collaboration agreements with Adimab, LLC, where a co-founder and former Chairperson of Alector is the Executive Chairman of Adimab.
- Alector has a consulting agreement with Dr. Richard Scheller, a member of the Board of Directors and Scientific Advisory Board.
Stakeholder Impact
- Shareholders are asked to vote on key proposals that will impact the company's governance and executive compensation.
- Employees are indirectly impacted through the executive compensation program and the company's overall performance.
- The outcome of the votes can influence investor confidence and the company's ability to attract and retain talent.
Next Steps
- Stockholders are urged to vote on the proposals outlined in the proxy statement.
- The company will hold its annual meeting on June 12, 2024.
- The company will announce voting results after the annual meeting.
Key Dates
| Date | Description |
|---|---|
| 2013 | Arnon Rosenthal co-founded Alector. |
| 2014 | Alector entered into an antibody research and development collaboration agreement with Adimab, LLC. |
| November 2018 | Alector adopted a Change in Control and Severance Agreement. |
| February 2019 | Alector became a publicly traded company. |
| March 2020 | Paula Hammond joined the Board of Directors. |
| September 2021 | Elizabeth Garofalo joined the Board of Directors. |
| December 2021 | Sara Kenkare-Mitra became President and Head of Research and Development. |
| February 2022 | Marc Grasso became Chief Financial Officer. |
| May 2022 | Gary Romano became Chief Medical Officer. |
| June 2023 | Louis J. Lavigne, Jr. became Chairperson of the Board of Directors. |
| September 2023 | Alector adopted a Compensation Recovery Policy. |
| March 2024 | Mark Altmeyer and Errol De Souza joined the Board of Directors. |
| April 16, 2024 | Record date for the Annual Meeting. |
| April 25, 2024 | Expected mailing date of the Notice of Internet Availability of Proxy Materials. |
| June 12, 2024 | Date of the 2024 Annual Meeting of Stockholders. |
| December 26, 2024 | Deadline for stockholder proposals for inclusion in the 2025 proxy statement. |
| February 9, 2025 | Earliest date for submitting notice of stockholder proposals not intended for inclusion in the 2025 proxy statement. |
| March 11, 2025 | Latest date for submitting notice of stockholder proposals not intended for inclusion in the 2025 proxy statement. |
Keywords
annual meeting, proxy statement, directors, executive compensation, Ernst & Young, stockholders, voting, Alector
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.